Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

In Pursuit of Unicorns: A Journey Through 50 Years of Biotechnology

BuchGebunden
506 Seiten
Englisch
"This book is about the history of emerging new therapies and preventions for a host of human diseases via biotechnology; the science that drives it and the people and companies who transformed that science into the biotechnologies we benefit from"--mehr

Produkt

Klappentext"This book is about the history of emerging new therapies and preventions for a host of human diseases via biotechnology; the science that drives it and the people and companies who transformed that science into the biotechnologies we benefit from"--
Details
ISBN/GTIN978-1-62182-498-5
ProduktartBuch
EinbandartGebunden
FormatGenäht
Erscheinungsjahr2024
Erscheinungsdatum17.09.2024
Seiten506 Seiten
SpracheEnglisch
Artikel-Nr.61351957
Rubriken
GenreMedizin

Autor

Tim Harris is a molecular biologist and biochemist. He started work in the biotech industry almost at its inception. He began his career in 1974, working on animal viruses, and was one of the first scientists to join the U.K. biotech company Celltech in 1981. Subsequently he spent nearly five years at Glaxo Group Research (now GSK) in the United Kingdom as Director of Biotechnology.
Tim has founded several biotech companies since moving to the United States in 1993 to be head of R&D at Sequana Therapeutics, a genomics company in San Diego. He founded and ran SGX Pharmaceuticals (acquired by Eli Lilly) and served briefly as the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland. Latterly, Tim moved to Biogen as SVP Translational Medicine in 2011, before joining the haematology spinout Bioverativ, as head of R&D in March 2017 before the company was acquired by Sanofi.
Tim is a presently a venture partner at SV Health Investors and actively works on behalf of several small biotechnology companies, some of which he founded. He has published more than 100 peer-reviewed research papers and reviews and has written many commentaries for BioCentury and other industry magazines.
Tim is married and has four children, four grandchildren, a cat, and a racing car. He is a citizen of both the United States and the United Kingdom and spends his time in Nahant, Massachusetts or on the Caribbean Island of Barbados.
This is his first book.